Core Viewpoint - Dongyangguang Pharmaceutical (600673) has seen a stock price increase of over 4%, attributed to rising flu activity in southern provinces and the approval of a new drug for chronic hepatitis B treatment [1] Group 1: Stock Performance - Dongyangguang Pharmaceutical's stock rose by 4.51%, reaching HKD 51.25, with a trading volume of HKD 20.6868 million [1] Group 2: Market Activity - The latest flu monitoring report from the Chinese Center for Disease Control and Prevention indicates an increase in flu activity in southern provinces and most northern provinces [1] Group 3: Product Development - Dongyangguang Pharmaceutical is known as the "king of flu drugs," with its oseltamivir (brand name: Kewai) holding a significant market share in China [1] - The company has received approval for clinical trials of its self-developed first-class new drug, HECN30227, which targets chronic hepatitis B [1] Group 4: Research and Development Focus - According to招商证券, the company's R&D is concentrated on three main areas: anti-infection, chronic diseases (metabolism), and oncology, with a rich pipeline of products [1] - The company’s existing products are experiencing rapid growth, marking the beginning of a new chapter in global innovation [1]